The biology of serotonin receptors: Focus on migraine pathophysiology and treatment

Canadian Journal of Neurological Sciences

Volumn 26, Issue SUPPL.3, 1999, Pages

  Hamel, Edith ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECEPTOR SUBTYPE; SEROTONIN 1 AGONIST; SEROTONIN RECEPTOR;

CONFERENCE PAPER; HEADACHE; HUMAN; INFLAMMATION; MIGRAINE; NEUROMODULATION; NEUROTRANSMISSION; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

EID: 0032741884     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0317167100000123     Document Type: Conference Paper

References (31)

1. Martin GR, Humphrey PPA. Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 1994; 33: 261-273.
2. Pandey SC, Davis JM, Pandey GN. Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates. J Psychiatry Neurosci 1995; 20: 215-225.
3. Gerhardt CC, van Heerikhuizen H. Functional characteristics of heterologously expressed 5-HT receptors. Eur J Pharmacol 1997; 334: 1-23.
4. Martin GR. Serotonin receptor involvement in the pathogenesis and treatment of migraine. In: Silberstein S, Goadsby PJ, eds. Headache Blue Books of Practical Neurology, Volume 17, Chapter 2. Butterworth-Heineman, 1997; 25-38.
5. Hoyer D, Martin G. 5-HT receptor classification and nomenclature: towards a harmonization with the human genome. Neuropharmacology 1997; 36: 419-428.
6. 1Dβ , receptor subtypes. Eur J Pharmacol 1995; 291:9-15.
7. 1P receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine. Life Sci 1997; 61: 2117-2126.
8. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales, TG and Kirkness, EF. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397:359-363.
9. Dahlöf CGH, Hargreaves RJ. Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia 1998; 18: 593-604.
10. 4 receptor: a place in the sun. Trends Pharmacol Sci 1992; 13: 141-145.
11. 7 receptor: orphan found. Trends Pharmacol Sci 1997; 18:104-107.
12. 7 receptor: a target for novel therapeutic avenues? Drugs 1998; 1: 302-310.
13. 7 receptor in cerebrovascular vasodilation: potential impact in migraine. Proc West Pharmacol Soc 1998; 41: 247-251.
14. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13: 307-311.
15. 1B/1D agonists inhibits trigeminal cell firing in the cat. Brain 1997; 120: 2171-2177.
16. Goadsby PJ. Is a central action of acute antimigraine drugs essential? Cephalalgia 1997; 17(Suppl): 10-11.
17. Fozard JR. The pharmacological basis of migraine treatment. In: Blau JN, ed. Migraine: Clinical and Research Aspects, Chapter 10. Baltimore: The Johns Hopkins University Press, 1987; 165-184.
18. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993; 33:48-56.
19. 1Dβ receptor subtype in human and bovine cerebral arteries. Mol Pharmacol 1993; 44: 242-246.
20. Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol 1996; 50: 219-223.
21. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997; 17: 833-842.
22. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.
23. Durham PL, Sharma RV and Russo AF. Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J Neurosci 1997; 17:9545-9553.
24. 3H]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 1996; 16: 317-322.
25. Fozard JR, Kalkman HO. 5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350: 225-229.
26. 2B or 5-HT2C receptor blockade? Life Sci 1994; 54: 641-644.
27. 2B receptors: an early step in the generation of migraine headache? Eur J Neurosci 1996;8:959-967.
28. 2C, receptors in human brain vessels: possible role in migraine headache. J Cereb Blood Flow Metab 1997; 17(Suppl 1): S351.
29. Wei EP, Moskowitz MA, Boccalini P, Contos HA. Calcitonin generelated peptide mediates nitroglycerin and sodium nitroprussideinduced vasodilation in feline cerebral arteries. Circ Res 1992; 70: 1313-1319.
30. Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998; 18: 27-32.
31. Cohen Z, Bouchelet I, Olivier A, et al. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacological characterization. J Cereb Blood Flow Metab 1999; 19: 908-917.